Artemisinin Research Center, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Nat Prod Rep. 2021 Jul 21;38(7):1243-1250. doi: 10.1039/d0np00079e.
Covering: Up to 2020 Artemisinin has made a significant contribution towards global malaria control since its initial discovery. Countless lives have been saved by this unique and miraculous molecule. In 2006, artemisinin-based combination therapies (ACTs) were recommended by the World Health Organization (WHO) as the first-line treatment for uncomplicated malaria infection and have since remained as the mainstays of the antimalarial treatment. Even so, substantial efforts to pursue better curative effects for the treatment of malaria have never ceased, particularly with regards to the circumstances surrounding the appearance of delayed clearance of malaria parasites by 3 day ACT treatments in South-East Asian countries. Strategies to further optimize artemisinin-based therapies, including synthesizing better artemisinin derivatives, developing advanced drug delivery systems, and diversifying artemisinin partner drugs, have been proposed over the past few years. Here, we provide an updated account of the continuous efforts in improving ACTs for better efficacy in curing malarial infection.
自最初发现青蒿素以来,它为全球疟疾控制做出了重大贡献。这种独特而神奇的分子挽救了无数生命。2006 年,世界卫生组织(WHO)推荐青蒿素类复方疗法(ACT)作为治疗无并发症疟疾感染的一线药物,此后一直是抗疟治疗的主要方法。即便如此,人们从未停止过追求更好的治疗效果来治疗疟疾,特别是在东南亚国家出现青蒿素类药物治疗 3 天后疟原虫清除延迟的情况下。过去几年,人们提出了进一步优化基于青蒿素的治疗方法的策略,包括合成更好的青蒿素衍生物、开发先进的药物输送系统以及使青蒿素联合用药多样化。在这里,我们提供了一个最新的关于不断努力改善 ACT 以提高治疗疟疾感染疗效的概述。